Report Overview

The size of the Pancreatic Cancer Therapeutics Market in the EU was worth USD 0.56 billion in 2019 and estimated to be growing at a CAGR of XX% to reach USD XX billion by 2028

Pancreatic Cancer is caused by the uncontrolled growth of cells results in the formation of lumps of tissue, referred to as tumors. The occurrence and mortality rate of pancreatic cancer is more in men than in women. Pancreatic Cancer is currently the 4th leading cause of death in the EU. Given the insuppressible nature of pancreatic cancer, treatments often return inefficient results. It is yet another barrier to the growth of the market. Technologies are yet to fully develop for the timely diagnosis of this cancer, resulting in the diagnosis of the majority of pancreatic cancer patients at an advanced stage of the disease. This explains the high mortality rates associated with pancreatic cancer. According to an estimation, only 12% to 15% of the patients are diagnosed early enough to be treated with surgical procedures, drugs, and chemotherapy. The biggest risk factor which leads to pancreatic cancer is smoking. Apart from lifestyle-dependent factors like alcohol consumption, obesity, and smoking, a personal or family history of pancreatitis or old age may result in a person being affected by pancreatic cancer



Market Growth Drivers

Increasing healthcare expenditure in the pancreatic cancer therapeutics would drive the EU market during the forecast period. The technological developments drug innovations with regard to pancreatic cancer are expected to grow. The major restraints include limited treatment options, the reason being the diagnosis of this cancer at advanced stages. Another reason which would hinder the market growth are low success rates in the clinical trials and adverse side effects and high toxicity of drugs